14. | MISCELLANEOUS PROVISIONS. |
(a) Proceeds from the sale of Shares pursuant to Purchase Rights will constitute general funds of the Company.
(b) A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, Shares subject to Purchase Rights unless and until the Participant’s Shares acquired upon exercise of Purchase Rights are recorded in the register of members of the Company.
(c) The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at will nature of a Participant’s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related Corporation to continue the employment of a Participant.
(d) This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of Delaware, without regard to conflict of law principles that would result in any application of any law other than the laws of Delaware.
As used in the Plan, the following definitions will apply to the capitalized terms indicated below:
(a) “2021 ESPP” shall have the meaning set forth in Section 1(a).
(b) “Ambrx Cayman” means Ambrx Biopharma (Cayman) Inc. (f/k/a Ambrx Biopharma Inc. prior to the Effective Date), a Cayman Islands exempted company.
(c) “Board” means the Board of Directors of the Company.
(d) “Capital Shares” means each and every class of shares of the Company, regardless of the number of votes per share.
(e) “Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Shares subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through any merger, consolidation, reorganization, recapitalization, reincorporation, share dividend, dividend in property other than cash, large nonrecurring cash dividend, share split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, which, in any such case, the Board determines, in its sole discretion, affects the Common Stock such that an adjustment pursuant to Section 11(a) here of is appropriate.
(f) “Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.
(g) “Committee” means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(d).
(h) “Common Stock” means the common stock, par value $0.0001 per share, of the Company.
(i) “Company” means Ambrx Biopharma, Inc., a Delaware corporation (or any successor company).
(j) “Contributions” means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions.
8